Pr Evkeeza®
evinacumab for injection

ALBERTA

PrEVKEEZA® (evinacumab for injection) is eligible for public reimbursement in Alberta for patients with HoFH through Alberta Blue Cross with special authorization (request form).

What Is EVKEEZA and How Does It Work?

EVKEEZA is the first and only ANGPTL3 inhibitor indicated as an adjunct to diet and other LDL-C lowering therapies for the treatment of adult and pediatric patients aged 6 months and older with homozygous familial hypercholesterolemia (HoFH).

The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.

Please consult the Product Monograph at https://www.ultragenyx.ca/evkeezaproductmonograph for important information relating to warnings and precautions, adverse reactions, breastfeeding, drug interactions, and dosing information.

The Product Monograph is also available by calling us at 1-833-388-5872.

The EVKEEZA Reimbursement Criteria for the Alberta Drug Benefit List Program Are as Follows:

SPECIAL AUTHORIZATION

Special authorization may be provided, as an adjunct to diet and other Low Density Lipoprotein Cholesterol (LDL-C) lowering therapies, for the treatment of adult and pediatric patients aged 5 years and older if the following clinical criteria and conditions are met:

1. Patient has a genetically confirmed diagnosis of Homozygous Familial Hypercholesterolemia (HoFH), defined as:
   - Documented functional mutation or mutations in both low-density lipoprotein receptor (LDLR) alleles, OR
   - Documented homozygous or compound heterozygous mutations in apolipoprotein B (ApoB) or proprotein convertase subtilisin/kexin type 9 (PCSK9), or low-density lipoprotein receptor adaptor protein 1 (LDLRAP1), or at least 2 such variants at different loci.

   AND

2. Patient must have elevated LDL-C despite an adequate trial of other accessible lipid-lowering therapies, defined as:
   - LDL-C greater than 1.8 mmol/L at baseline for adult patients and greater than 3.4 mmol/L for pediatric patients.

- For coverage, this drug must be prescribed by a Specialist in Endocrinology, Cardiology or Internal Medicine (“Specialist”).
- A baseline LDL-C must be provided upon initial request, after all other treatment options of lipid-lowering therapies have been exhausted.
- Initial coverage may be approved for one dose of 15 mg/kg every four weeks for a period of 24 weeks.

- Patients will be limited to receiving one dose of evinacumab per prescription at their pharmacy.

For continued coverage beyond 24 weeks, the patient must meet the following criteria:

- Patient has achieved a reduction in LDL-C from baseline that is considered clinically beneficial by the Specialist.

Continued coverage may be approved for a period of 12 months.

For more information on applying for EVKEEZA® coverage, we can arrange an appointment at your convenience, or you can go to the UltraCare website. You can also find the UltraCare Enrolment Form on the UltraCare website.